Jan 17, 2017

Winners & losers from Facebook's live video pivot

Recode reports that Facebook may stop paying publishers to make live videos, after dishing out more than $50 million to over 140 publishers in FB Live contracts last year.

Why?:

  • Diminishing ROI: A large international marketing campaign targeted to everyday users could suggest that Facebook sees diminishing returns on investment in paying publishers to create content that everyday users can now create for free.
  • Long-form video pivot: This could be yet another signal by Facebook that it is readying its plans to distribute its long-form content to compete with the likes of Netflix or Amazon. In 2016, the tech giant rolled out a video tab on its platform and said they were exploring "funding some seed video content."

Winners: You. This could be good news for everyday users who are being inundated with live content flooding their streams on numerous social platforms. The push for publishers to create enough Facebook Live content to fulfill contract needs often meant publishing video that wasn't suited for a Facebook Live audience, like hour-long live discussions and panels at events.

Losers: Amazon, Netflix, and TV networks. Facebook's pivot to long-form, professionally-produced could be aimed to gobble audience and advertising dollars from companies that create long-form content, like Amazon, Netflix, and TV networks. For TV networks, the television audience is already accustomed to engaging on Facebook. A new Nielsen study published Tuesday says Facebook users average 3.9 TV-related engagements on Facebook each day. Facebook's head of creative strategy said last year that funding long-form video "takes advantage of mobile and the social interaction unique to Facebook."

Smart take: Expect publishers to pull back live content efforts if a new business model isn't introduced for them to monetize on the platform. As CNN's Executive Vice President Andrew Morse said earlier this month, "It's going to be hard for us to continue to do Facebook Live long-term if we can't figure out how to monetize it, because we're able to monetize our video really well in other places."

Go deeper

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 10:30 a.m. ET: 5,618,829 — Total deaths: 351,146 — Total recoveries — 2,311,404Map.
  2. U.S.: Total confirmed cases as of 10:30 a.m. ET: 1,681,793 — Total deaths: 98,933 — Total recoveries: 384,902 — Total tested: 14,907,041Map.
  3. Public health: Fauci says data is “really quite evident” against hydroxychloroquine for coronavirus — Nearly half of Americans say someone in their household has delayed medical care.
  4. Tech: Zipline drones deliver masks to hospitals; vaccines could be next
  5. Business: The downsides of remote work could diminish recent gains — PPP failed to get money to industries and areas most in need.
  6. 🏒Sports: NHL unveils 24-team playoff plan to return from hiatus.
  7. What should I do? When you can be around others after contracting the coronavirus — Traveling, asthma, dishes, disinfectants and being contagiousMasks, lending books and self-isolatingExercise, laundry, what counts as soap — Pets, moving and personal healthAnswers about the virus from Axios expertsWhat to know about social distancingHow to minimize your risk.
  8. Other resources: CDC on how to avoid the virus, what to do if you get it, the right mask to wear.

Subscribe to Mike Allen's Axios AM to follow our coronavirus coverage each morning from your inbox.

Updated 19 mins ago - Politics & Policy

Fauci: Data is “really quite evident” against hydroxychloroquine for coronavirus

Anthony Fauci told CNN Wednesday that the scientific data "is really quite evident now about the lack of efficacy" of hydroxychloroquine as a coronavirus treatment.

Driving the news: The comments came in response to news that France on Wednesday banned the use of hydroxychloroquine to treat the virus, after a large retrospective study in The Lancet found an increased risk of heart problems and death among coronavirus patients who took the anti-malarial drug.

Trump has turned Big Tech's speech rules into a political football

Illustration: Lazaro Gamio/Axios

Twitter made headlines Tuesday after labeling two election-related tweets from President Trump as potentially misleading — the company’s first action against the president’s tweets, which often test its policies on misinformation and abuse.

The big picture: Twitter's unprecedented move, which swiftly drew Trump's fury, was just one of four controversies over the last 24 hours involving tech platforms grappling with free speech issues. And all of them, Axios' Sara Fischer and I report, reflect what a partisan issue the policing of social media content has become.